Alteogen, Inc
{{company.company_channel.channel_name}}
Media Room
{{company.company_name_local}}
{{company.company_channel.channel_name}}
Company Profile
Media Room
Alteogen enters into an Exclusive License Agreement to Develop and Commercialize Subcutaneous ENHERTU® Enabled by Alteogen's Hybrozyme™ Technology 2024-11-11 08:07
Alteogen Receives Ministry of Food and Drug Safety (MFDS) Approval for Tergase® 2024-07-08 21:00
Altos Biologics Files for Approval of Aflibercept Biosimilar 2024-07-02 08:00
Alteogen's Tergase® (Novel Recombinant Human Hyaluronidase Injection) Shows Excellent Immunogenicity Profile 2023-09-05 20:00
Altos Biologics, a Subsidiary of Alteogen, Completed Patient Enrollment in Global Phase 3 Clinical Trial of Eylea® Biosimilar in Neovascular Age-related Macular Degeneration 2023-02-22 22:00
1